Skip to main content

SafeBeat Rx

Latest News

SafeBeat Rx UCSF Clinical Trial begins Enrollment

In March, we began our UCSF clinical trial, which focuses on obtaining real user feedback on our application and reviewing algorithm results against the UCSF providers. The SafeBeat application aims

Vinko Buble has joined as Head of Backend Engineering

We are thrilled to welcome Vinko Buble to SafeBeat Rx as our new Head of Backend Engineering!  Vinko has had over two decades of experience as a Full Stack Software Engineer, Architect, and

SafeBeat Rx CEO, Dr. Rachita Navara, presents at annual Heart Rhythm Society Conference

In a remarkable milestone for SafeBeat, Dr. Rachita Navara, the esteemed co-founder of SafeBeat, presented at the Heart Rhythm Society’s annual conference, the largest arrhythmia conference in

SafeBeat Rx

MedTech Innovator, the world’s largest accelerator of medical technology companies, today announced the 50 companies selected to participate in the organization’s flagship four-month Accelerator

SafeBeat Rx CEO, Dr. Rachita Navara, recognized for AI Leadership & Entrepreneurship Awards by VentureBeat

Since 2019, VentureBeat has been honoring the women leaders, mentors, researchers and entrepreneurs who are transforming the AI industry

The Pulse Celebrates SafeBeat Rx CEO, Dr. Rachita Navara

Rachita Navara, CEO and cofounder of Safebeat RX, received a first funding of $120K. SafeBeat Rx replaces a hospitalization with a take-home kit that combines FDA-approved wearables with life-saving

Zillionize Invests in SafeBeat Rx

Zillionize Invests in SafeBeat Rx – Using cutting-edge engineering to transform cardiac care

Olin College of Engineering recognizes SafeBeat Rx CEO, Dr. Rachita Navara

As valedictorian and Outstanding Senior Student at the acclaimed Signature School in Indiana, Dr. Rachita Navara ’11 had her pick of top engineering schools from MIT to Caltech—but for her, Olin stood

SafeBeat Rx CEO highlighted by MIT’s venture firm, Engine

We are building machine learning technology to expand access to important, often life-saving heart medications. Fortunately, this is an area of healthcare where the priorities of all the major